Tralokinumab Efficacy Over 1 Year in Adults with Moderate-to-Severe Atopic Dermatitis: Pooled Data from Two Phase III Trials-Reference-Cited by-同舟云学术

Tralokinumab Efficacy Over 1 Year in Adults with Moderate-to-Severe Atopic Dermatitis: Pooled Data from Two Phase III Trials

Published:2023-09-08 Issue:6 Volume:24 Page:939-952
ISSN:1175-0561
Container-title:American Journal of Clinical Dermatology
language:en
Short-container-title:Am J Clin Dermatol

Author:

Simpson Eric L.,Pink Andrew E.,Blauvelt Andrew,Gooderham Melinda,Armstrong April W.,Worm Margitta,Katoh Norito,Peris Ketty,Puig Luis,Barbarot Sébastien,Mark Thomas,Steffensen Louise Abildgaard,Tindberg Ann-Marie,Wollenberg Andreas

Funder

LEO Pharma

Ludwig-Maximilians-Universität München

Publisher

Springer Science and Business Media LLC

Subject

Dermatology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s40257-023-00806-3.pdf

Reference27 articles.

1. Silverberg JI, Gelfand JM, Margolis DJ, Boguniewicz M, Fonacier L, Grayson MH, et al. Patient burden and quality of life in atopic dermatitis in US adults: a population-based cross-sectional study. Ann Allergy Asthma Immunol. 2018;121(3):340–7.

2. Stander S. Atopic dermatitis. N Engl J Med. 2021;384(12):1136–43.

3. Wollenberg A, Christen-Zach S, Taieb A, Paul C, Thyssen JP, de Bruin-Weller M, et al. ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children. J Eur Acad Dermatol Venereol. 2020;34(12):2717–44.

4. Futamura M, Leshem YA, Thomas KS, Nankervis H, Williams HC, Simpson EL. A systematic review of Investigator Global Assessment (IGA) in atopic dermatitis (AD) trials: many options, no standards. J Am Acad Dermatol. 2016;74(2):288–94.

5. Wei EX, Kirsner RS, Eaglstein WH. End points in dermatologic clinical trials: a review for clinicians. J Am Acad Dermatol. 2016;75(1):203–9.

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Chronic Pruritus;JAMA;2024-06-25

2. Matching-Adjusted Indirect Comparison of the Efficacy at Week 32 of Tralokinumab and Dupilumab in the Treatment of Moderate-to-Severe Atopic Dermatitis;Dermatology and Therapy;2024-04